Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation

Angewandte Chemie - International Edition

Volumn 53, Issue 47, 2014, Pages 12930-12935

  Karnthaler Benbakka, Claudia ^a   Groza, Diana ^b   Kryeziu, Kushtrim ^b   Pichler, Verena ^a   Roller, Alexander ^a   Berger, Walter ^a,b,c   Heffeter, Petra ^a,b,c   Kowol, Christian R ^a,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anticancer drugs; Cobalt; Hypoxia; Prodrugs; Tyrosine kinase inhibitors

Indexed keywords

AMINO ACIDS; BIOACTIVITY; CELL CULTURE; COBALT; DRUG INTERACTIONS; DRUG THERAPY; ENZYME INHIBITION; ENZYMES; TUMORS;

ANTICANCER ACTIVITIES; ANTICANCER DRUG; CHELATING MOIETIES; EPIDERMAL GROWTH FACTOR RECEPTORS; HYPOXIA; PRODRUGS; RECEPTOR TYROSINE KINASE; TYROSINE KINASE INHIBITOR;

CHEMICAL ACTIVATION;

ANTINEOPLASTIC AGENT; COBALT; EPIDERMAL GROWTH FACTOR RECEPTOR; ORGANOMETALLIC COMPOUND; PROTEIN KINASE INHIBITOR;

ANIMAL; ANOXIA; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; MOUSE; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; SCID MOUSE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL CULTURE;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; COBALT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICE, SCID; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; ORGANOMETALLIC COMPOUNDS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84941065402     PISSN: 14337851     EISSN: 15213773     Source Type: Journal    
DOI: 10.1002/anie.201403936     Document Type: Article

References (27)

1. M. K. Paul, A. K. Mukhopadhyay, Int. J. Med. Sci. 2004, 1, 101-115.
2. S. V. Sharma, D. W. Bell, J. Settleman, D. A. Haber, Nat. Rev. Cancer 2007, 7, 169-181.
3. V. Chandregowda, A. K. Kush, G. C. Reddy, Eur. J. Med. Chem. 2009, 44, 3046-3055.
4. C. M. Rocha-Lima, H. P. Soares, L. E. Raez, R. Singal, Cancer Control 2007, 14, 295-304.
5. a) G. Lurje, H. J. Lenz, Oncology 2009, 77, 400-410;
6. b) T. Li, R. Perez-Soler, Targ. Oncol. 2009, 4, 107-119.
7. I. Tranoy-Opalinski, A. Fernandes, M. Thomas, J. P. Gesson, S. Papot, Anticancer Agents Med. Chem. 2008, 8, 618-637.
8. a) M. A. Naylor, P. Thomson, Mini-Rev. Med. Chem. 2001, 1, 17-29;
9. b) W. R.Wilson, M. P. Hay, Nat. Rev. Cancer 2011, 11, 393-410;
10. c) J. M. Brown, W. R. William, Nat. Rev. Cancer 2004, 4, 437-447.
11. I. Ott, R. Gust, Arch. Pharm. 2007, 340, 117-126.
12. a) D. C. Ware, B. D. Palmer, W. R. Wilson, W. A. Denny, J. Med. Chem. 1993, 36, 1839-1846;
13. b) U. Jungwirth, C. R. Kowol, B. K. Keppler, C. G. Hartinger, W. Berger, P. Heffeter, Antioxid. Redox Signaling 2011, 15, 1085-1127.
14. M. C. Heffern, N. Yamamoto, R. J. Holbrook, A. L. Eckermann, T. J. Meade, Curr. Opin. Chem. Biol. 2013, 17, 189-196.
15. a) G. O. Ahn, K. J. Botting, A. V. Patterson, D. C. Ware, M. Tercel, W. R. Wilson, Biochem. Pharmacol. 2006, 71, 1683-1694;
16. b) J. Y. C. Chang, R. J. Stevenson, G. L. Lu, P. J. Brothers, G. R. Clark, W. A. Denny, D. C. Ware, Dalton Trans. 2010, 39, 11535-11550;
17. c) J. B. Milbank, R. J. Stevenson, D. C. Ware, J. Y. C. Chang, M. Tercel, G. O. Ahn, W. R. Wilson, W. A. Denny, J. Med. Chem. 2009, 52, 6822-6834.
18. D. Baiz, T. A. Pinder, S. Hassan, Y. Karpova, F. Salsbury, M. E. Welker, G. Kulik, J. Med. Chem. 2012, 55, 8038-8046.
19. a) C. M. Discafani, M. L. Carroll, M. B. Floyd, Jr., I. J. Hollander, Z. Husain, B. D. Johnson, D. Kitchen, M. K. May, M. S. Malo, A. A. Minnick, Jr., R. Nilakantan, R. Shen, Y. F.Wang, A. Wissner, L. M. Greenberger, Biochem. Pharmacol. 1999, 57, 917-925;
20. b) T. Barf, A. Kaptein, J. Med. Chem. 2012, 55, 6243-6262.
21. H. R. Tsou, N. Mamuya, B. D. Johnson, M. F. Reich, B. C. Gruber, F. Ye, R. Nilakantan, R. Shen, C. Discafani, R. DeBlanc, R. Davis, F. E. Koehn, L. M. Greenberger, Y. F. Wang, A. Wissner, J. Med. Chem. 2001, 44, 2719-2734.
22. A. Bourkoula, M. Paravatou-Petsotas, A. Papadopoulos, I. Santos, H. J. Pietzsch, E. Livaniou, M. Pelecanou, M. Papadopoulos, I. Pirmettis, Eur. J. Med. Chem. 2009, 44, 4021-4027.
23. R. D. Archer, B. P. Cotsoradis, Inorg. Chem. 1965, 4, 1584-1589.
24. J. D. Moyer, E. G. Barbacci, K. K. Iwata, L. Arnold, B. Boman, A. Cunningham, C. DiOrio, J. Doty, M. J. Morin, M. P. Moyer, M. Neveu, V. A. Pollack, L. R. Pustilnik, M. M. Reynolds, D. Sloan, A. Theleman, P. Miller, Cancer Res. 1997, 57, 4838-4848.
25. L. J. Boucher, J. C. Bailar, J. Inorg. Nucl. Chem. 1965, 27, 1093-1099.
26. Crystal data for [1·HClO4]ClO4: C26H31BrCl2CoN5O12, mr= 815.30, crystal size=0.040 × 0.049 × 0.312 mm, triclinic, P1, a= 7.7893(4), b=12.3702(7), c=16.7844(9) Å, α=82.404(2), β= 78.264(2), γ=76.685(2)8, V=1534.70(14) Å3, Z=2, ρcalcd= 1.764 gcm-3, μ=2.108 mm-1, l(MoKa)=0.71073 Å, T=100 K, 2qmax=60.29°, 58928 reflections measured, 9022 unique (Rint= 0.0552), R1=0.0500, wR2=0.1269, largest difference peak and hole: 1.084 and -0.702 eA-3. CCDC 994541 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data-request/cif.
27. Y. Wang, M. Ohh, J. Cell. Mol. Med. 2010, 14, 496-503.